CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: March 5, 2019
Result type: Reports
Project Number: SR0607-000
Product Line: Reimbursement Review

Generic Name: ataluren

Brand Name: Translarna

Manufacturer: PTC Therapeutics Canada ULC

Indications: Dystrophinopathy

Manufacturer Requested Reimbursement Criteria1:

​For the treatment of dystrophinopathy resulting from a nonsense mutation in the dystrophin gene.

Submission Type: Initial

Project Status: Cancelled

Biosimilar: No

Fee Schedule: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.